You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

840 Results
Document
Document
Document
Document
Document
Document
Document
Document
Document
Document
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Intent: Palliative
Funding:
Exceptional Access Program
    encorafenib - In combination with cetuximab or panitumumab in previously treated BRAF V600E-mutated metastatic colorectal cancer, according to clinical criteria
New Drug Funding Program
    Panitumumab - In Combination with Encorafenib for Previously Treated Metastatic Colorectal Cancer
Apr 2024

Pages